References of "SAUTOIS, Brieuc"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPhase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Seront, E.; Rottey, S.; Filleul, B. et al

in BJU International (2016)

BACKGROUND: Excessive activation of the PI3K/Akt/mTOR pathway is frequently observed in transitional cell carcinoma (TCC) due to a loss of PTEN and/or activating mutation of PIK3CA. Allosteric mTOR ... [more ▼]

BACKGROUND: Excessive activation of the PI3K/Akt/mTOR pathway is frequently observed in transitional cell carcinoma (TCC) due to a loss of PTEN and/or activating mutation of PIK3CA. Allosteric mTOR inhibition by everolimus resulted in modest efficacy in advanced TCC. In different TCC cell lines, it has been shown that PI3K inhibition enhanced the efficacy of mTOR inhibitors with a synergistic effect observed mainly in cells with PI3K/Akt/mTOR pathway alterations. OBJECTIVES: To assess in a multicenter phase II trial the safety and efficacy of BEZ235, an oral pan-class I PI3K and mTOR complex1/2 inhibitor, in locally advanced or metastatic TCC after failure of platinum-based therapy. PATIENTS AND METHODS: Patients with locally advanced or metastatic TCC progressing after platinum therapy were prospectively stratified by PI3K/Akt/mTOR pathway alterations, defined as PTEN loss and PIK3CA mutation. All received BEZ235 until progressive disease (PD) or unacceptable toxicity. The primary endpoint was the progression free survival (PFS) rate at 16 weeks. This study was, however, closed prematurely due to BEZ235 being withdrawn from further development. RESULTS: Twenty patients (18 without and two with PI3K/Akt/mTOR alterations) were enrolled and received BEZ235. One partial response (5%) and two cases of stable disease (10%) were observed, all in patients without PI3K/mTOR pathway alterations. The PFS rate at 8 and 16 weeks was 15% and 10%, respectively; the median PFS was 62 days (95% confidence interval (CI) 53 - 110 days; range 38 - 588 days) and the median OS was 127 days (95% CI 58 - 309 days; range 41 - 734 days). Among the 90% of patients who presented with any grade drug-related adverse events, 50% presented with grade 3 - 4 adverse events including stomatitis (15%), fatigue (5%), nausea (5%), diarrhea (5%), renal failure (5%), cutaneous rash (5%), hepatotoxicity (5%) and hypertension (5%), CONCLUSIONS: BEZ235 showed modest clinical activity and an unfavorable toxicity in patients with advanced and pretreated TCC. However, a minority of patients presented clinical benefit, suggesting that a complete blockade of the PI3K/ mTOR axis could improve outcome in some specific patients. Furthermore, this study showed that molecular stratification of patients for personalized medicine before treatment is feasible. This article is protected by copyright. All rights reserved. [less ▲]

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailWeekly cisplatin with radiotherapy for locally advanced head and neck squamous cell carcinoma.
SAUTOIS, Brieuc ULg; SCHROEDER, Hélène ULg; MARTIN, Marie ULg et al

in JBUON (2016), 21(4), 979-988

Background Although commonly used for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) concomitant radio-chemotherapy (RT-CT) with weekly cisplatin has not been definitely ... [more ▼]

Background Although commonly used for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) concomitant radio-chemotherapy (RT-CT) with weekly cisplatin has not been definitely studied. We conducted a single centre retrospective study with the aim to evaluate efficacy and acute toxicity of definitive concomitant RT-CT with 40 mg/m² weekly cisplatin in patients with locally advanced HNSCC with a particular emphasis on radiotherapy modality (conventional or accelerated) and dose of cisplatin delivered. Method One hundred and twelve consecutive patients were included. They were given cisplatin 40 mg/m²/week concomitantly with conventionally fractionated (CFRT) (N = 33) or accelerated (ART) (N = 79) radiotherapy. Results Radiotherapy was delivered according to the treatment plan in 104 patients and full dose was given to 107 patients. A median cumulative cisplatin dose of 240 mg/m² was delivered to patients treated with CFRT and of 200 mg/m² to those treated with ART. Overall complete response rate was 81.3%. With a median follow up of 38.4 months, median overall survival was 75 months, not influenced by radiotherapy type or cisplatin dose received. The most clinically significant grade 3 or 4 acute toxicities were stomatitis (35.7%), neutropenia (25%), anemia (12.5%) and acute kidney injury (5.4%). Conclusion Our study shows that a median cumulative dose of 200 mg/m² cisplatin can be safely delivered using a weekly regimen to patients treated with concomitant radiotherapy (CFRT or ART). Efficacy results and toxicity compare favourably with those described with triweekly cisplatin RT-CT suggesting that a randomized comparison should be undertaken. [less ▲]

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailRandomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels, Jean-Pascal Henry; Van Maanen, Aline; Vandenbulcke, Jean-Marie et al

in Oncologist (2016), 21

LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients ... [more ▼]

LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%). BACKGROUND: Cabazitaxel is a second-generation taxane that improves the survival of patients with metastatic castrate-resistant prostate cancer following docetaxel therapy. Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. In this randomized phase II trial, we investigated cabazitaxel in patients with recurrent SCCHN. METHODS: Patients with incurable SCCHN with progression after platinum-based therapy were randomly assigned to cabazitaxel every 3 weeks (cycle 1, 20 mg/m2, increased to 25 mg/m2 for subsequent cycles in the absence of nonhematological adverse events [AEs] greater than grade 2 and hematological AEs greater than grade 3) or methotrexate (40 mg/m2/week). The patients were stratified according to their performance status and previous platinum-based chemotherapy for palliation versus curative intent. The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks. RESULTS: Of the 101 patients, 53 and 48, with a median age of 58.0 years (range, 41-80), were randomly assigned to cabazitaxel or methotrexate, respectively. The PFSR at 18 weeks was 13.2% (95% confidence interval [CI], 5%-25%) for cabazitaxel and 8.3% (95% CI, 2%-20%) for methotrexate. The median progression-free survival was 1.9 months in both arms. The median overall survival was 5.0 and 3.6 months for cabazitaxel and methotrexate, respectively. More patients experienced serious adverse events with cabazitaxel than with methotrexate (54% vs. 36%). The most common drug-related grade 3-4 AE in the cabazitaxel arm was febrile neutropenia (17.3%). CONCLUSION: This study did not meet its primary endpoint. Cabazitaxel has low activity in recurrent SCCHN. [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailEXPLORATION ET TRAITEMENT D’UN CARCINOME EPIDERMOIDE GANGLIONNAIRE CERVICAL SANS PRIMITIF DECELE
WERENNE, Xavier ULg; SAUTOIS, Brieuc ULg; DEMEZ, Pierre ULg et al

in Revue Médicale de Liège (2014), 69(Supp 1), 58-62

A l’heure actuelle, le bilan à réaliser après décou - verte d’une adénopathie cervicale est bien codifié. Le PET- scan, dans un premier temps controversé, s’affirme étude après étude comme un élément ... [more ▼]

A l’heure actuelle, le bilan à réaliser après décou - verte d’une adénopathie cervicale est bien codifié. Le PET- scan, dans un premier temps controversé, s’affirme étude après étude comme un élément essentiel. La stratégie de traitement pratiquée dans la plupart des centres consiste en un évidemment cervical suivi de radiothérapie portant sur les muqueuses pharyngées ainsi que sur les relais ganglion - naires cervicaux bilatéraux avec éventuelle association à une chimiothérapie. Celle-ci est ajoutée en fonction de facteurs anatomo-pathologiques de mauvais pronostic, mais elle n’a pas fait la preuve de sa supériorité. De multiples études de phase II aboutissent d’ailleurs à des conclusions opposées. En dehors de données issues d’études randomisées, le traitement aujourd’hui se décide par analogie à ceux qui sont appliqués lorsque le site primitif tumoral est identifié dans la sphère ORL. [less ▲]

Detailed reference viewed: 104 (12 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration.
Sautois, Brieuc ULg; GENNIGENS, Christine ULg

in Revue Médicale de Liège (2013), 68(2), 94-6

Docetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line ... [more ▼]

Docetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line treatment may be appropriate. Until recently no standard treatment was approved in this setting and mitoxantrone was commonly used. Three new drugs have shown benefit in randomised phase 3 multicenter clinical trials published since 2010. Cabazitaxel, abiraterone and enzalutamide were shown to prolong overall survival of men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. Although still modest these results were deemed clinically significant and led to the reimbursement of Jevtana (cabazitaxel) and Zytiga (abiraterone) in Belgium in 2012. [less ▲]

Detailed reference viewed: 143 (6 ULg)
Full Text
Peer Reviewed
See detailPhase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
Seront, E.; Rottey, S.; Sautois, Brieuc ULg et al

in Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (2012), 23(10), 2663-70

BACKGROUND: This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum ... [more ▼]

BACKGROUND: This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. PATIENTS AND METHODS: Thirty-seven patients with advanced TCC received everolimus 10 mg/day until progressive disease (PD) or unacceptable toxicity. The primary end point was the disease control rate (DCR), defined as either stable disease (SD), partial response (PR), or complete response at 8 weeks. Angiogenesis-related proteins were detected in plasma and changes during everolimus treatment were analyzed. PTEN expression and PIK3CA mutations were correlated to disease control. RESULTS: Two confirmed PR and eight SD were observed, resulting in a DCR of 27% at 8 weeks. Everolimus was well tolerated. Compared with patients with noncontrolled disease, we observed in patients with controlled disease a significant higher baseline level of angiopoietin-1 and a significant early plasma decrease in angiopoietin-1, endoglin, and platelet-derived growth factor-AB. PTEN loss was observed only in patients with PD. CONCLUSIONS: Everolimus showed clinical activity in advanced TCC. The profile of the plasma angiogenesis-related proteins suggested a role of the everolimus antiangiogenic properties in disease control. PTEN loss might be associated with everolimus resistance. [less ▲]

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailRadiation-induced malignant peripheral nerve sheat tumors – a report of 2 cases
PHAN BA, Remy ULg; BELACHEW, Shibeshih ULg; JEDIDI, Zayd ULg et al

Poster (2011, May)

We discuss the case of two patients who developped delayed malignant peripheral nerve sheath tumor (MPNST) following radiotherapy. Case report: the first patient is a sixty year-old woman with a 2 years ... [more ▼]

We discuss the case of two patients who developped delayed malignant peripheral nerve sheath tumor (MPNST) following radiotherapy. Case report: the first patient is a sixty year-old woman with a 2 years history of right cervicobrachial pain and weakness. The neurological examination depicted severe weakness, atrophy and loss of sensation in the right C5 and C6 territories. A subclavicular hardened and enlarged lymph node was noted. Her past medical history was notable for a Hodgkin’s disease (HD) treated with radiation therapy (>40Gy) 35 years earlier. Brachial plexus MRI revealed a tumoral mass arising from the right brachial plexus. Biopsy of the subclavicular mass revealed a poorly differentiated malignant tumour consisting of spindle cells showing moderate polymorphism and a high mitotic index. Immunohistochemistry showed positivity for the S-100 protein, the CD56 and for the epithelial membrane antigen (EMA) and a diagnosis of MPNST of the brachial plexus was proposed. The second case is a 36 year-old man referred for a history of right sciatic neuralgia that appeared 3 years earlier. The medical history of the patient was notable for a right seminoma, treated by orchidectomy and prophylactic radiotherapy (24 Gy) 5 years earlier. The neurologic examination revealed right L5 and S1 radicular territories involvement, and the CT of the pelvis demonstrated a nodular mass at the level of the greater sciatic foramen. A surgical biopsy was performed and the neuropathological findings were consistent with a diagnosis of low-grade MPSNT. Discussion: MPNSTs are rare tumors accounting for 3 to 10% of all tissues sarcomas. Half of the cases described are sporadic, while the other half tend to appear in patients suffering from tumor prone conditions, such as neurofibromatosis type 1. Although secondary neoplasms are known complications of radiotherapy, descriptions of peripheral nerve sheath tumors (PNST) are scarce. The exact pathophysiology of radiation-induced PNSTs remains unclear but vascular alterations, direct damages to axon or Schwann cell and nerve compression by soft tissue fibrosis are thought to play a role. Although surgical removal sometimes followed by chemotherapy is the mainstay of MPNSTs, they usually carry a poor prognosis. Our 2 cases emphasize that the possibility of radiation-induced MPNST has to be kept in mind when investigating a localized neuropathy in a previously irradiated area. [less ▲]

Detailed reference viewed: 65 (6 ULg)
Full Text
Peer Reviewed
See detailChimiothérapie néoadjuvante dans les cancers "tête et cou"
Piret, Pascal ULg; Demez, Pierre ULg; Moreau, Pierre ULg et al

in Revue Médicale de Liège (2010)

Les cancers de la sphère oto-rhino-laryngologique représentent 5 % des cancers et sont assez souvent diagnostiqués à un stade avancé. Leur traitement nécessite une approche multidisciplinaire comprenant ... [more ▼]

Les cancers de la sphère oto-rhino-laryngologique représentent 5 % des cancers et sont assez souvent diagnostiqués à un stade avancé. Leur traitement nécessite une approche multidisciplinaire comprenant la chirurgie, la radiothérapie et/ ou la chimiothérapie. La chimiothérapie permet d'améliorer la survie lorsqu'elle est appliquée en association avec la radiothérapie (6,5% de bénéfice absolu en survie globale) dans les maladies localement avancées. La chimiothérapie d'induction ou néoadjuvante a fait l'objet de nombreuses études, mais n'a jamais clairement montré de bénéfice excepté dans le but d'une préservation laryngée. Les nouveaux schémas de chimiothérapie comprenant un taxane ont fait renaître un intérêt pour le traitement d'induction. Quelques études randomisées ont montré un bénéfice en termes de taux de réponse, survie sans maladie ou survie globale lorsque le docetaxel est associé au cisplatine-5FU. Cependant, le bénéfice de l'ajout d'un traitement d'induction à la radiochimiothérapie concomitante reste controversé. De nouvelles études sont en cours. A l'heure actuelle, la chimiothérapie d'induction n'est recommandée en routine que dans la perspective d'une préservation laryngée. [less ▲]

Detailed reference viewed: 171 (14 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique.
Gennigens, Christine ULg; Sautois, Brieuc ULg; Jerusalem, Guy ULg

in Revue Médicale de Liège (2010), 65(4), 212-6

Renal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, immunotherapy (interferon and/or interleukin-2) was the only approved option in the metastatic setting. Better ... [more ▼]

Renal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, immunotherapy (interferon and/or interleukin-2) was the only approved option in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF ("Vascular Endothelial Growth Factor") and VEGFR inhibitors. They are now the usual treatment in first line. Until recently, no standard treatment was available after failure under or after these inhibitors. Everolimus (Afinitor), a mTOR ("mammalian Target Of Rapamycin") inhibitor, has just been validated and reimbursed in this setting. In this paper, we will review the mechanism of action and the clinical results of everolimus. [less ▲]

Detailed reference viewed: 153 (6 ULg)
Full Text
Peer Reviewed
See detailAnticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites.
Gennigens, Christine ULg; Collignon, Joëlle ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 264-7

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation ... [more ▼]

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation, growth and metastasis have led to the identification of specific pathways playing a role in the pathophysiology of cancer. New drugs specifically developed to control these targets are collectively named "targeted therapies". Two types of targeted therapies are available: kinase (mainly tyrosine kinase) inhibitors (suffix -nib) are small molecules binding directly to the intracellular kinase domain and acting as competitive inhibitor of ATP binding and monoclonal antibodies (suffix -mab) directed towards specific cell surface receptors or their ligands to prevent receptor activation. This paper will only review monoclonal antibodies (mabs). Thirty years after their discovery mAbs have become efficient therapeutic tools. Progress in molecular engineering as well as improved knowledge of cell signalling pathways together with a better selection of the targets turned them into valuable treatments. Several mAbs are currently licensed for the treatment of hematological or solid malignancies and many others are expected in the near future. [less ▲]

Detailed reference viewed: 143 (7 ULg)
Full Text
Peer Reviewed
See detailPlace des anticorps monoclonaux dans le traitement des tumeurs de la tete et du cou.
Sautois, Brieuc ULg; Martin, Marie ULg; Demez, Pierre ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 284-6

Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer. Cetuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with ... [more ▼]

Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer. Cetuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with radiotherapy alone as radical treatment of locally advanced head and neck cancer. It is now reimbursed in Belgium after multidisciplinary discussion if cisplatin is contra-indicated. In the metastatic setting adding cetuximab to platinum based chemotherapy improves overall survival as compared with chemotherapy alone, a first-time event over a 30-year period, unfortunately not yet accessible to the Belgian patients. Other monoclonal antibodies targeting EGFR or VEGF are also currently under investigation while cetuximab is being explored in the induction, the maintenance or the post-operative radiotherapy settings. [less ▲]

Detailed reference viewed: 91 (9 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide.
Mievis, Carole ULg; Jansen, Nicolas ULg; Schleich, FLorence ULg et al

in Revue Médicale de Liège (2009), 64(4), 179-81

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic ... [more ▼]

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic agents such as gemcitabine, taxanes, anthracyclines. We report the case of a 50-year-old man with metastatic prostate cancer who developed two consecutive radiation recall dermatitis episodes triggered by oral cyclophosphamide. They occurred 4 to 5 weeks after palliative radiotherapy on bone metastasis. Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide. [less ▲]

Detailed reference viewed: 285 (11 ULg)
Full Text
Peer Reviewed
See detailLes tumeurs de la sphere ORL: standards de traitement et nouvelles approches en radiotherapie.
Coucke, Philippe ULg; Piret, Pascal ULg; Werenne, Xavier ULg et al

in Revue Médicale de Liège (2008), 63(3), 141-8

We intend to review the general value of radiotherapy in the management of head and neck cancer. Our aim is to define a treatment protocol which is evidence-based and therefore of use in daily clinical ... [more ▼]

We intend to review the general value of radiotherapy in the management of head and neck cancer. Our aim is to define a treatment protocol which is evidence-based and therefore of use in daily clinical practice. There is general agreement on the efficacy of the concomitant schedules combining radiotherapy and chemotherapy, both in the adjuvant setting as well as in the exclusive non-surgical approach. This however does not preclude further research aiming at optimizing the therapeutic index. As far as neoadjuvant chemotherapy is concerned, applied prior to radical local treatment, there are no conclusive data available which allows us to implement this treatment option in routine clinical practice. This approach deserves further investigations and patients should be entered in well designed prospective randomized trials. [less ▲]

Detailed reference viewed: 201 (26 ULg)
Full Text
Peer Reviewed
See detailTraitement chimiothérapique actuel du cancer de l'ovaire
Paulus, Astrid ULg; Gennigens, Christine ULg; Fillet, Georges ULg et al

in Revue Médicale de Liège (2007), 62(9), 539-47

Epithelial ovarian cancer is frequently diagnosed at advanced-stage disease and chemotherapy is nearly always required. Optimally debulked patients may need adjuvant chemotherapy while, most of the time ... [more ▼]

Epithelial ovarian cancer is frequently diagnosed at advanced-stage disease and chemotherapy is nearly always required. Optimally debulked patients may need adjuvant chemotherapy while, most of the time this chemotherapy will be given to those with advanced-stage disease. Also relapses will be treated differently whether they occur early or late in the course of the disease. This paper reviews medical treatment modalities according to stage based on published data. Maintenance and consolidation treatments are also discussed. Finally a brief insight into new therapeutic tools is also given. [less ▲]

Detailed reference viewed: 246 (20 ULg)
Full Text
Peer Reviewed
See detailActualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles
Jerusalem, Guy ULg; Rorive, Andrée ULg; Gennigens, Christine ULg et al

in Revue Médicale de Liège (2007), 62 Spec No

The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and ... [more ▼]

The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and HER2 overexpression. Trastuzumab, a monoclonal antibody, is the only registered antiHER2 treatment in Belgium. The association of trastuzumab with chemotherapy is now the recommended adjuvant treatment for early breast cancer overexpressing HER2. Other antiHER2 medications are available and some will probably be registered soon. Angiogenesis is another potential target for improving the treatment results. The CHU Liege, as a reference center for the systemic treatment of solid tumors, participates in many international trials in order to validate these new approaches. The highest quality of care is required to be in compliance with the conduct of these clinical trials. Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials. [less ▲]

Detailed reference viewed: 145 (9 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques en oncologie: l'essor des therapeutiques ciblees
Gennigens, Christine ULg; Sautois, Brieuc ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 391-8

Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted ... [more ▼]

Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted therapies" indicates that treatments are directed against specific molecular targets that play a major role in the activation of cell division and in the growth and dissemination of tumors. In particular, targeted therapies were developed against epithelial growth factor receptors and angiogenesis. We can expect specifise therapies against many other targets in the near future. Several drugs have obtained a marketing license. Predictive factors for tumor response and long term outcome should be developed for a better selection of the patient population who will benefit from these treatments. New imaging techniques are under development in order to assess the molecular response to these new approaches. [less ▲]

Detailed reference viewed: 262 (12 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Recidive d'une tumeur testiculaire mixte 15 ans apres le traitement initial.
Smeets, Laurent ULg; De Roover, Arnaud ULg; Sautois, Brieuc ULg

in Revue Médicale de Liège (2006), 61(10), 671-4

We report the case of a patient with a symptomatic retroperitoneal tumor. The patient had undergone, 15 years earlier, an orchiectomy and three cycles of chemotherapy for a testicular mixed germ cell ... [more ▼]

We report the case of a patient with a symptomatic retroperitoneal tumor. The patient had undergone, 15 years earlier, an orchiectomy and three cycles of chemotherapy for a testicular mixed germ cell tumor. Histology after radical surgical excision revealed a metastasis of mature teratoma. The 183 month interval between initial treatment and relapse is one of the longest ever reported. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailL'image du mois. Une image de "lâcher de ballons" à l'imagerie thoracique
Wauters, O.; Sautois, Brieuc ULg; Fillet, Georges ULg

in Revue Médicale de Liège (2005), 60

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailTraitement du cancer du sein chez la personne âgée
Gillain, Sophie ULg; Gennigens, Christine ULg; Sautois, Brieuc ULg et al

in Revue Médicale Suisse (2004), 62

Le cancer du sein représente chez la personne âgée une pathologie fréquente. Le choix du traitement dépend de l'âge physiologique, des pathologies et comorbidités associées ainsi que du niveau de vie et d ... [more ▼]

Le cancer du sein représente chez la personne âgée une pathologie fréquente. Le choix du traitement dépend de l'âge physiologique, des pathologies et comorbidités associées ainsi que du niveau de vie et d'autonomie. De plus, selon les facteurs histopronostiques (récepteurs aux oestrogènes et à la progestérone, la surexpression du cerb-B2) on décidera éventuellement du schéma thérapeutique le plus approprié. Chez la personne âgée, la chirurgie (mastectomie ou tumorectomie), la radiothérapie et l'hormonothérapie trouvent leur place. Au-delà de 70 ans, la place de la chimiothérapie est incertaine. En effet, les patientes de plus de 70 ans sont sous-représentées dans les études randomisées. [less ▲]

Detailed reference viewed: 282 (6 ULg)